FLT3 inhibition by olverembatinib (HQP1351) downregulates MCL-1 and synergizes with BCL-2 inhibitor lisaftoclax (APG-2575) in preclinical models of FLT3-ITD mutant acute myeloid leukemia
Sign Up to like & getrecommendations! Published in 2021 at "Translational Oncology"
DOI: 10.1016/j.tranon.2021.101244
Abstract: Introduction FLT3-ITD mutations occur in approximately 25% of patients with acute myeloid leukemia (AML) and are associated with poor prognosis. Despite initial efficacy, short duration of response and high relapse rates limit clinical use of… read more here.
Keywords: apg 2575; itd mutant; hqp1351; flt3 itd ... See more keywords
Abstract 4217: Synergy of tyrosine kinase inhibitor HQP1351 and MDM2-P53 antagonist, APG-115, in preclinical models ofFLT3mutant andTP53wild-type acute myeloid leukemia
Sign Up to like & getrecommendations! Published in 2020 at "Cancer Research"
DOI: 10.1158/1538-7445.am2020-4217
Abstract: HQP1351 is a novel, orally bioavailable multi-kinase inhibitor targeting BCR-ABL, KIT, and FLT3. Currently, HQP1351 is in phase II clinical trials in relapsed and refractory chronic myeloid leukemia (CML) patients by targeting BCR-ABL. Besides, HQP1351… read more here.
Keywords: myeloid leukemia; apg 115; kinase; hqp1351 ... See more keywords